NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has received special 510(k) clearance from the US Food and Drug Administration for its Tissue of Origin (TOO) gene expression test.
...and receive Daily News bulletins.
Already have an account?Login Now.
In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.
This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.
With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.